MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530537 | Name: ML-7 HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML-7 is a MLCK inhibitor. ML-7 inhibits smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM. ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner.

Chemical Structure

ML-7 HCl
ML-7 HCl
CAS#110448-33-4

Theoretical Analysis

MedKoo Cat#: 530537

Name: ML-7 HCl

CAS#: 110448-33-4

Chemical Formula: C15H18ClIN2O2S

Exact Mass:

Molecular Weight: 452.74

Elemental Analysis: C, 39.79; H, 4.01; Cl, 7.83; I, 28.03; N, 6.19; O, 7.07; S, 7.08

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 weeks
200mg USD 750.00 2 weeks
500mg USD 1,250.00 2 weeks
1g USD 1,950.00 2 weeks
2g USD 2,950.00 2 weeks
5g USD 4,250.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ML-7 HCl; ML-7 hydrochloride; ML-7; ML 7; ML7.
IUPAC/Chemical Name
hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine, monohydrochloride
InChi Key
KDDALCDYHZIZMH-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H17IN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18;/h1-2,4-7,17H,3,8-11H2;1H
SMILES Code
O=S(N1CCNCCC1)(C2=C3C=CC=C(I)C3=CC=C2)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC50=300 nM).
In vitro activity:
TBD
In vivo activity:
These symptoms of AS (atherosclerosis) were significantly improved following treatment with ML7, as demonstrated in the ML7 group. Hematoxylin & eosin and immunohistochemical staining indicated that ML7 was able to decrease the expression of MLCK and MLC phosphorylation in the arterial wall of rabbits fed a high‑fat diet. Reference: Mol Med Rep. 2015 Sep;12(3):4109-4116. https://pubmed.ncbi.nlm.nih.gov/26096176/
Solvent mg/mL mM comments
Solubility
DMF 30.0 66.26
DMSO 46.4 102.51
DMSO:PBS (pH 7.2) (1:1) 0.5 1.10
Ethanol 1.0 2.21
Water 1.4 3.16
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 452.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Cheng X, Wang X, Wan Y, Zhou Q, Zhu H, Wang Y. Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis. Mol Med Rep. 2015 Sep;12(3):4109-4116. doi: 10.3892/mmr.2015.3973. Epub 2015 Jun 22. PMID: 26096176; PMCID: PMC4526030. 2. Luh C, Kuhlmann CR, Ackermann B, Timaru-Kast R, Luhmann HJ, Behl C, Werner C, Engelhard K, Thal SC. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem. 2010 Feb;112(4):1015-25. doi: 10.1111/j.1471-4159.2009.06514.x. Epub 2009 Nov 27. PMID: 19943851.
In vitro protocol:
TBD
In vivo protocol:
1. Cheng X, Wang X, Wan Y, Zhou Q, Zhu H, Wang Y. Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis. Mol Med Rep. 2015 Sep;12(3):4109-4116. doi: 10.3892/mmr.2015.3973. Epub 2015 Jun 22. PMID: 26096176; PMCID: PMC4526030. 2. Luh C, Kuhlmann CR, Ackermann B, Timaru-Kast R, Luhmann HJ, Behl C, Werner C, Engelhard K, Thal SC. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem. 2010 Feb;112(4):1015-25. doi: 10.1111/j.1471-4159.2009.06514.x. Epub 2009 Nov 27. PMID: 19943851.
1: Zhou Y, Zhang S, Deng S, Dai C, Tang S, Yang X, Li D, Zhao K, Xiao X. ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. Toxicol Mech Methods. 2016;26(1):11-21. doi: 10.3109/15376516.2015.1090513. PubMed PMID: 26446980. 2: Cherlet M, Gleich S, Dewerchin H, Nauwynck H, Daminet S, De Backer P, Croubels S. Quantitative analysis of an anti-viral immune escape compound ML-7 in feline plasma using ultra performance liquid chromatography/electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:118-26. doi: 10.1016/j.jchromb.2012.08.014. PubMed PMID: 22925719. 3: Lin HB, Cadete VJ, Sawicka J, Wozniak M, Sawicki G. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteomics. 2012 Sep 18;75(17):5386-95. doi: 10.1016/j.jprot.2012.06.016. PubMed PMID: 22749930. 4: Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, Thieme H. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res. 2005 Jun;80(6):837-45. PubMed PMID: 15939040. 5: Odani K, Kobayashi T, Ogawa Y, Yoshida S, Seguchi H. ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner. Histochem Cell Biol. 2003 May;119(5):363-70. PubMed PMID: 12750906. 6: Kelley SJ, Thomas R, Dunham PB. Candidate inhibitor of the volume-sensitive kinase regulating K-Cl cotransport: the myosin light chain kinase inhibitor ML-7. J Membr Biol. 2000 Nov 1;178(1):31-41. PubMed PMID: 11058685. 7: Kozgunova E, Higashiyama T, Kurihara D. Cytokinesis defect in BY-2 cells caused by ATP-competitive kinase inhibitors. Plant Signal Behav. 2016 Oct 2;11(10):e1238547. PubMed PMID: 27662076; PubMed Central PMCID: PMC5257169. 8: Zhang Y, Li J, Chi Y, Li M, Pan X, Zhang Q, He X, Liu Y. [Myosin light chain kinase involved in change of intestinal mucosal barrier function in nonalcoholic steatohepatitis mice model]. Zhonghua Nei Ke Za Zhi. 2015 May;54(5):434-8. Chinese. PubMed PMID: 26080824. 9: Tian B, Brumback LC, Kaufman PL. ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey Eye. Exp Eye Res. 2000 Dec;71(6):551-66. PubMed PMID: 11095907. 10: Shi W, Xu C, Hussain M, Wu F, Lu M, Wu X, Tang L, Wu X, Wu J. Inhibition of Myosin Light-Chain Kinase Enhances the Clearance of Lipopolysaccharide-Induced Lung Inflammation Possibly by Accelerating Neutrophil Apoptosis. Shock. 2017 Mar 7. doi: 10.1097/SHK.0000000000000863. [Epub ahead of print] PubMed PMID: 28272166. 11: Natarajan P, Crothers JM Jr, Rosen JE, Nakada SL, Rakholia M, Okamoto CT, Forte JG, Machen TE. Myosin IIB and F-actin control apical vacuolar morphology and histamine-induced trafficking of H-K-ATPase-containing tubulovesicles in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol. 2014 Apr 15;306(8):G699-710. doi: 10.1152/ajpgi.00316.2013. PubMed PMID: 24578340; PubMed Central PMCID: PMC3989701. 12: Rossi JL, Todd T, Bazan NG, Belayev L. Inhibition of Myosin light-chain kinase attenuates cerebral edema after traumatic brain injury in postnatal mice. J Neurotrauma. 2013 Oct 1;30(19):1672-9. doi: 10.1089/neu.2013.2898. PubMed PMID: 23984869; PubMed Central PMCID: PMC3787387. 13: Bil-Lula I, Lin HB, Biały D, Wawrzyńska M, Diebel L, Sawicka J, Woźniak M, Sawicki G. Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury. J Cell Mol Med. 2016 Jun;20(6):1086-94. doi: 10.1111/jcmm.12827. PubMed PMID: 26992120; PubMed Central PMCID: PMC4882990. 14: Mackenzie AC, Kyle DD, McGinnis LA, Lee HJ, Aldana N, Robinson DN, Evans JP. Cortical mechanics and myosin-II abnormalities associated with post-ovulatory aging: implications for functional defects in aged eggs. Mol Hum Reprod. 2016 Jun;22(6):397-409. doi: 10.1093/molehr/gaw019. PubMed PMID: 26921397; PubMed Central PMCID: PMC4884917. 15: Wang B, Yan Y, Zhou J, Zhou Q, Gui S, Wang Y. A novel all-trans retinoid acid derivatives inhibits the migration of breast cancer cell lines MDA-MB-231 via myosin light chain kinase involving p38-MAPK pathway. Biomed Pharmacother. 2013 Jun;67(5):357-62. doi: 10.1016/j.biopha.2013.03.016. PubMed PMID: 23602051. 16: Eikemo H, Moltzau LR, Hussain RI, Nguyen CH, Qvigstad E, Levy FO, Skomedal T, Osnes JB. CaMKII in addition to MLCK contributes to phosphorylation of regulatory light chain in cardiomyocytes. Biochem Biophys Res Commun. 2016 Feb 26;471(1):219-25. doi: 10.1016/j.bbrc.2016.01.132. PubMed PMID: 26809094. 17: Droy-Lefaix MT, Bueno L, Caron P, Belot E, Roche O. Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats: a protective effect of a myosin light chain kinase inhibitor. Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2705-10. doi: 10.1167/iovs.12-10193. PubMed PMID: 23518768; PubMed Central PMCID: PMC3632265. 18: Liu X, Xu J, Mei Q, Han L, Huang J. Myosin light chain kinase inhibitor inhibits dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2013 Jan;58(1):107-14. doi: 10.1007/s10620-012-2304-3. PubMed PMID: 22777616. 19: Wu F, Guo X, Xu J, Wang W, Li B, Huang Q, Su L, Xu Q. Role of myosin light chain and myosin light chain kinase in advanced glycation end product-induced endothelial hyperpermeability in vitro and in vivo. Diab Vasc Dis Res. 2016 Mar;13(2):137-44. doi: 10.1177/1479164115610469. PubMed PMID: 26607798. 20: Nepiyushchikh ZV, Chakraborty S, Wang W, Davis MJ, Zawieja DC, Muthuchamy M. Differential effects of myosin light chain kinase inhibition on contractility, force development and myosin light chain 20 phosphorylation of rat cervical and thoracic duct lymphatics. J Physiol. 2011 Nov 15;589(Pt 22):5415-29. doi: 10.1113/jphysiol.2011.218446. PubMed PMID: 21930597; PubMed Central PMCID: PMC3240881.